To confirm the limited effect of NALT TRMs on EBV control, we specifically targeted CD103+ TRMs, which comprise a major part of the TRMs in the NALT (Figure 2D), by treatment with an anti-CD103 antibody (Ber-ACT8) beginning 3 weeks after i.n. EBV infection. Here, ITGAE is linked to Epstein-Barr virus infection.